Radiofrequency Ablation of Adenomyosis

Learn more about:
Related Clinical Trial
The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis Long-term Use of Mifepristone in the Treatment of Adenomyosis Radiofrequency Ablation of Adenomyosis Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

Radiofrequency Ablation of Adenomyosis

Official Title

RAFA Trial: Radiofrequency Ablation of Adenomyosis

Brief Summary

      To observe the effects of radiofrequency ablation on adenomyosis through the pathological
      analysis of treated tissue that has been removed during planned hysterectomy.

Detailed Description

      The ProVu™ System (Hologic, Inc., Boston, MA) is designed and cleared by the FDA as a
      treatment method for soft tissue, including the treatment of symptomatic uterine fibroids.
      After locating the general region of the target tissue, a laparoscopic ultrasound transducer
      is placed on the serosal surface of the uterus to identify the size, location, and number of
      focal adenomyosis (or adenomyomas). Under ultrasound guidance, the treatment probe
      (handpiece) is inserted through the serosal surface and into the target tissue. The electrode
      array containing multiple thermocouples is then deployed according to the size of the target
      tissue and the position is verified using the ultrasound transducer. Once correctly placed,
      the surgeon initiates ablation by pressing the foot pedal. Continuous temperature feedback is
      displayed on the generator screen. For safety purposes, dispersive pads are placed on the
      patient's thighs to disperse electrical current. If the target tissue is irregular or large,
      the needle array is retracted and the probe repositioned within the same area under
      ultrasound guidance. The ablation is repeated until the area of interest is ablated.
      Overlapping ablations may be required. At the conclusion of the final ablation, the surgeon
      retracts the array withdraws the probe through the serosal surface of the uterus while
      coagulating the track to avoid bleeding. Once hemostasis is confirmed and all target tissue
      has been treated, the surgeon proceeds with the planned hysterectomy and the tissue is
      examined by a pathologist to assess the ablation zones within the adenomyoma or focal

Study Type


Primary Outcome

Post-operative evidence of adenomyoma tissue ablation as assessed by pathological analysis




RF Treatment

Study Arms / Comparison Groups

 RF Treatment
Description:  At the time of the subject's trans-abdominal or laparoscopic hysterectomy, the ProVu System will be used to apply RF treatment to one or two adenomas, focal areas of adenomyosis, or diffuse adenomyosis.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

July 14, 2022

Completion Date

February 2024

Primary Completion Date

October 2023

Eligibility Criteria

        Inclusion Criteria:

          -  planning to undergo an abdominal, laparoscopic, or robotic-assisted hysterectomy due
             to benign conditions

          -  uterus < 16 weeks gestational size if undergoing a laparoscopic or robotic procedure
             (no size limit for patients planning to undergo a transabdominal hysterectomy)

          -  at least one area of focal or diffuse adenomyosis or adenomyomas that is/are
             contralateral to any fibroids as determined by MRI

          -  able to provide informed consent

          -  suitable candidates for surgery (have passed a standard pre-operative health

          -  English speaking

        Exclusion Criteria:

          -  require emergent hysterectomy or vaginal hysterectomy

          -  have a uterus > 16 weeks gestational size if undergoing a laparoscopic or robotic
             procedure (no size limit for patients planning to undergo a transabdominal

          -  have fibroids in the proximity of the target adenomyosis (same side, similar location)

          -  are not appropriate surgical candidates as determined during pre-operative health

          -  are unable or unwilling to undergo a hysterectomy

          -  are pregnant or lactating

          -  are under the age of 18 years

          -  have active pelvic inflammatory disease

          -  have a history of gynecologic malignancy within the past 3 years

          -  are unable to give informed consent

          -  have an implantable uterine or fallopian tube device for contraception

          -  are not English speaking




18 Years - N/A

Accepts Healthy Volunteers



Kimberly Kho, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

University of Texas Southwestern Medical Center


 Hologic, Inc.

Study Sponsor

Kimberly Kho, MD, Principal Investigator, UT Southwestern Medical Center

Verification Date

July 2022